Off-Label Marketing Claims Against Schering Tossed

Law360, New York (July 14, 2009, 12:00 AM EDT) -- A federal judge has thrown out a putative class action accusing Schering-Plough Corp. of causing economic losses to a group of health and welfare funds, third-party payors, and individual consumers by illegally marketing its drugs Intron-A and Temodar for off-label uses, ruling that the plaintiffs failed to prove their theories of injury.

In an decision Friday, Judge Stanley Chesler of the U.S. District Court for the District of New Jersey disagreed with the plaintiffs' contention that the pharmaceutical giant was liable merely because it promoted the...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.